PMID- 35617964
OWN - NLM
STAT- MEDLINE
DCOM- 20220617
LR  - 20240216
IS  - 1097-4180 (Electronic)
IS  - 1074-7613 (Print)
IS  - 1074-7613 (Linking)
VI  - 55
IP  - 6
DP  - 2022 Jun 14
TI  - Dendritic cells can prime anti-tumor CD8(+) T cell responses through major 
      histocompatibility complex cross-dressing.
PG  - 982-997.e8
LID - S1074-7613(22)00187-X [pii]
LID - 10.1016/j.immuni.2022.04.016 [doi]
AB  - Antigen cross-presentation, wherein dendritic cells (DCs) present exogenous 
      antigen on major histocompatibility class I (MHC-I) molecules, is considered the 
      primary mechanism by which DCs initiate tumor-specific CD8(+) T cell responses. 
      Here, we demonstrate that MHC-I cross-dressing, an antigen presentation pathway 
      in which DCs acquire and display intact tumor-derived peptide:MHC-I molecules, is 
      also important in orchestrating anti-tumor immunity. Cancer cell MHC-I expression 
      was required for optimal CD8(+) T cell activation in two subcutaneous tumor 
      models. In vivo acquisition of tumor-derived peptide:MHC-I molecules by DCs was 
      sufficient to induce antigen-specific CD8(+) T cell priming. Transfer of 
      tumor-derived human leukocyte antigen (HLA) molecules to myeloid cells was 
      detected in vitro and in human tumor xenografts. In conclusion, MHC-I 
      cross-dressing is crucial for anti-tumor CD8(+) T cell priming by DCs. In 
      addition to quantitatively enhancing tumor antigen presentation, MHC 
      cross-dressing might also enable DCs to more faithfully and efficiently mirror 
      the cancer cell peptidome.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - MacNabb, Brendan W
AU  - MacNabb BW
AD  - Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
FAU - Tumuluru, Sravya
AU  - Tumuluru S
AD  - Committee on Cancer Biology, University of Chicago, Chicago, IL 60637, USA.
FAU - Chen, Xiufen
AU  - Chen X
AD  - Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
FAU - Godfrey, James
AU  - Godfrey J
AD  - Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
FAU - Kasal, Darshan N
AU  - Kasal DN
AD  - Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
FAU - Yu, Jovian
AU  - Yu J
AD  - Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
FAU - Jongsma, Marlieke L M
AU  - Jongsma MLM
AD  - Department of Immunopathology, Sanquin Research, Amsterdam, the Netherlands; 
      Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the 
      Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
FAU - Spaapen, Robbert M
AU  - Spaapen RM
AD  - Department of Immunopathology, Sanquin Research, Amsterdam, the Netherlands; 
      Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the 
      Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
FAU - Kline, Douglas E
AU  - Kline DE
AD  - Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
FAU - Kline, Justin
AU  - Kline J
AD  - Committee on Immunology, University of Chicago, Chicago, IL 60637, USA; Committee 
      on Cancer Biology, University of Chicago, Chicago, IL 60637, USA; Department of 
      Medicine, University of Chicago, Chicago, IL 60637, USA. Electronic address: 
      jkline@medicine.bsd.uchicago.edu.
LA  - eng
GR  - P30 CA014599/CA/NCI NIH HHS/United States
GR  - R01 CA166770/CA/NCI NIH HHS/United States
GR  - T32 AI007090/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220525
PL  - United States
TA  - Immunity
JT  - Immunity
JID - 9432918
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Peptides)
SB  - IM
CIN - Immunity. 2022 Jun 14;55(6):965-967. PMID: 35704996
EIN - Immunity. 2022 Nov 8;55(11):2206-2208. PMID: 36351377
MH  - Antigen Presentation
MH  - Antigens, Neoplasm
MH  - Bandages
MH  - CD8-Positive T-Lymphocytes
MH  - Cross-Priming
MH  - *Dendritic Cells
MH  - Histocompatibility Antigens Class I
MH  - Humans
MH  - Major Histocompatibility Complex
MH  - *Neoplasms/metabolism
MH  - Peptides
PMC - PMC9883788
MID - NIHMS1805124
OTO - NOTNLM
OT  - MHC cross-dressing
OT  - anti-tumor immunity
OT  - antigen presentation
OT  - dendritic cell
COIS- Declaration of interests The authors declare no competing interests.
EDAT- 2022/05/27 06:00
MHDA- 2022/06/18 06:00
PMCR- 2023/06/14
CRDT- 2022/05/26 18:43
PHST- 2021/04/20 00:00 [received]
PHST- 2021/11/20 00:00 [revised]
PHST- 2022/04/28 00:00 [accepted]
PHST- 2022/05/27 06:00 [pubmed]
PHST- 2022/06/18 06:00 [medline]
PHST- 2022/05/26 18:43 [entrez]
PHST- 2023/06/14 00:00 [pmc-release]
AID - S1074-7613(22)00187-X [pii]
AID - 10.1016/j.immuni.2022.04.016 [doi]
PST - ppublish
SO  - Immunity. 2022 Jun 14;55(6):982-997.e8. doi: 10.1016/j.immuni.2022.04.016. Epub 
      2022 May 25.